OBESITY RELATED HYPERTENSION - PHARMACOTHERAPY REGIMEN AND BLOOD PRESSURE CONTROL AMONG YOUNG ADULT PATIENTS IN POLAND AND GERMANY.

PACZKOWSKA, ANNA; HOFFMANN, KAROLINA; BRYL, WIESŁAW; MARZEC, KINGA; RAAKOW, JONAS; PROSS, MATTHIAS; KOPCIUCH, DOROTA; ZAPRUTKO, TOMASZ; RATAJCZAK, PIOTR; NOWAKOWSKA, ELŻBIETA; KUS, KRZYSZTOF

The aim of this study was to analyze the pharmacotherapy regimen and evaluate the blood pressure control in obese inpatients in Poland and Germany. The cross-sectional international multicenter study was conducted at selected health care facilities in Germany and Poland. The target group consisted of 256 patients (120 patients from Germany and 136 patients from Poland) aged 18-40 years, hospitalized for obesity-related hypertension in the year 2019. The number of hypertensive drugs used for obesity-related hypertension treatment was comparable in both study groups of patients (2.76 ± 1.24 patients from Germany, 2.59 ± 1.44 patients from Poland). ACEIs were significantly more frequently used by patients from Germany (p < 0.001). The following antihypertensive drugs: diuretics, calcium channel antagonists, fixed-dose combination drugs, and a-blockers, were significantly more frequently used by Polish patients (p < 0.001). As a result of the applied treatment, 52.5% of patients from Germany and 60.3% from Poland achieved the desired degree of blood pressure normalization. Systolic and diastolic blood pressure values, number of antihypertensive drugs used, duration of hospitalization due to uncontrolled hypertension and blood pressure control were associated with body mass index. Blood pressure control rates in obese patients are improving with the progress of hypertension pharmacotherapy and with the patient's better access to newer generation drugs.

OBESITY; HYPERTENSION; BLOOD pressure; CALCIUM; ANTIHYPERTENSIVE agents

Acta Poloniae Pharmaceutica, 2020, Vol 77, Issue 5, p815

0001-6837

Academic Journal

10.32383/appdr/128000